EP Patent

EP3760623A1 — Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof

Assigned to F Hoffmann La Roche AG · Expires 2021-01-06 · 5y expired

What this patent protects

Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure:and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features de…

USPTO Abstract

Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure:and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Drugs covered by this patent

Patent Metadata

Patent number
EP3760623A1
Jurisdiction
EP
Classification
—
Expires
2021-01-06
Drug substance claim
No
Drug product claim
No
Assignee
F Hoffmann La Roche AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.